OUR PURPOSE PIONEERING SCIENCE COMMUNITY REPORTING 93 PROMOTING ENVIRONMENTAL SUSTAINABILITY BIOGEN 2021 YEAR IN REVIEW PATIENTS OUR PEOPLE ENVIRONMENT – Engaging with regulators around packaging requirements – we found that the end customer location impacts each product’s environmental footprint. This not only reflects the distance to transport products, but also varying country requirements such as patient information cards that consume more paper. Patient inserts also require greater land use, energy for manufacturing and greater shipping weight. Over time, we may be able to engage with regulators and others to explore options to meet patient safety and health education goals while lessening environmental impacts. – Working across the value chain – biologics are temperature sensitive and require a secure cold chain management process from manufacturing to delivery. We identified significant energy use differences across Biogen suppliers and, as part of our net zero supply chain goals, we will engage suppliers in our Responsible Supplier Program. This can help suppliers address their energy usage and processes such as injection molding, which have high energy demands. Looking forward, we see opportunities to explore embedded assumptions around end-of-life product disposal practices and to conduct additional product LCAs to advance our goals for the environment, the patient experience and human health. Focusing on water and waste Managing water responsibly Water plays a critical role in many aspects of Biogen’s business, including in our production processes to sterilize and clean equipment and our HVAC system, specifically cooling towers. We are working to reduce our dependence on water, recycle more of it and make sure it adheres to the highest quality and safety standards before being returned to the environment. For example, we use grey water from the Town of Cary, North Carolina, for irrigation which, while not a significant volume, reflects our efforts in this area. As a result of efforts like this, from 2019 to 2021, we decreased our water use across Biogen operations by 15%. We use the World Wildlife Fund’s Water Risk Filter tool to complete site water risk assessments, understand water risks among critical suppliers and learn how both may change under various climate scenarios. Based on the water risk assessment, water scarcity is identified as a low risk at all our major facilities. We transparently report our water policies, programs and progress to CDP. Limiting pharmaceuticals in the environment Stakeholders have expressed concern about pharmaceuticals in the environment, and notably, watersheds and oceans around the world. Biogen follows the EU’s Strategic Approach to Pharmaceuticals in the Environment via our Green Chemistry program, incentives for green design, waste reduction and wastewater treatment, among other efforts. Since the pharmaceutical supply chain can play a role, Biogen is incorporating considerations around this issue into our Responsible Supplier Program . As a result of its life cycle analysis, Biogen is exploring changes like reductions in product materials and packaging that meets customer preferences and patient needs. Analysis – Our product lifecycle